Thereby, oropharyngeal cancers showed the highest percentage of p16-positive cases (54%, 42/78, defined as p16-IRS ≥ 7), followed by oral cavity cancers (47%, 8/17), hypopharyngeal cancers (39%, 9/23), and laryngeal cancers (34%, 12/35; Figure 6). This evidence concerns the gene CDKN2A and hypopharynx cancer.